(RTTNews) - Sandoz announced the European Medicines Agency has accepted the application for high concentration formulation 100 mg/mL of its biosimilar Hyrimoz for regulatory review. The company noted ...
Basel, July 21, 2022 – Sandoz, a global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) has accepted for review its Supplemental Biologics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results